Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase‐4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes : A subgroup analysis of the randomized CAROLINA trial

Information
References (0)
Discussion (0)
Files

Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase‐4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes : A subgroup analysis of the randomized CAROLINA trial - RWTH-CONV-244589

Comments (0) | Reviews (0)

You are not authorized to comment or review.

Similar records

h1

h2

h3

h4

h5

h6

RWTH

Kontakt

RWTH Publications

Allgemeines